Product: Nephrin Antibody
Catalog: AF7951
Description: Rabbit polyclonal antibody to Nephrin
Application: WB IF/ICC
Reactivity: Human, Mouse
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 135 kDa, 150 kDa; 135kD(Calculated).
Uniprot: O60500
RRID: AB_2844314

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Nephrin Antibody detects endogenous levels of total Nephrin.
RRID:
AB_2844314
Cite Format: Affinity Biosciences Cat# AF7951, RRID:AB_2844314.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CNF; Nephrin; Nephrosis 1 congenital Finnish type; Nephrosis 1, congenital, Finnish type (nephrin); NPHN; NPHN_HUMAN; NPHS 1; Nphs1; Renal glomerulus specific cell adhesion receptor; Renal glomerulus-specific cell adhesion receptor;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O60500 NPHN_HUMAN:

Specifically expressed in podocytes of kidney glomeruli.

Sequence:
MALGTTLRASLLLLGLLTEGLAQLAIPASVPRGFWALPENLTVVEGASVELRCGVSTPGSAVQWAKDGLLLGPDPRIPGFPRYRLEGDPARGEFHLHIEACDLSDDAEYECQVGRSEMGPELVSPRVILSILVPPKLLLLTPEAGTMVTWVAGQEYVVNCVSGDAKPAPDITILLSGQTISDISANVNEGSQQKLFTVEATARVTPRSSDNRQLLVCEASSPALEAPIKASFTVNVLFPPGPPVIEWPGLDEGHVRAGQSLELPCVARGGNPLATLQWLKNGQPVSTAWGTEHTQAVARSVLVMTVRPEDHGAQLSCEAHNSVSAGTQEHGITLQVTFPPSAIIILGSASQTENKNVTLSCVSKSSRPRVLLRWWLGWRQLLPMEETVMDGLHGGHISMSNLTFLARREDNGLTLTCEAFSEAFTKETFKKSLILNVKYPAQKLWIEGPPEGQKLRAGTRVRLVCLAIGGNPEPSLMWYKDSRTVTESRLPQESRRVHLGSVEKSGSTFSRELVLVTGPSDNQAKFTCKAGQLSASTQLAVQFPPTNVTILANASALRPGDALNLTCVSVSSNPPVNLSWDKEGERLEGVAAPPRRAPFKGSAAARSVLLQVSSRDHGQRVTCRAHSAELRETVSSFYRLNVLYRPEFLGEQVLVVTAVEQGEALLPVSVSANPAPEAFNWTFRGYRLSPAGGPRHRILSSGALHLWNVTRADDGLYQLHCQNSEGTAEARLRLDVHYAPTIRALQDPTEVNVGGSVDIVCTVDANPILPGMFNWERLGEDEEDQSLDDMEKISRGPTGRLRIHHAKLAQAGAYQCIVDNGVAPPARRLLRLVVRFAPQVEHPTPLTKVAAAGDSTSSATLHCRARGVPNIVFTWTKNGVPLDLQDPRYTEHTYHQGGVHSSLLTIANVSAAQDYALFTCTATNALGSDQTNIQLVSISRPDPPSGLKVVSLTPHSVGLEWKPGFDGGLPQRFCIRYEALGTPGFHYVDVVPPQATTFTLTGLQPSTRYRVWLLASNALGDSGLADKGTQLPITTPGLHQPSGEPEDQLPTEPPSGPSGLPLLPVLFALGGLLLLSNASCVGGVLWQRRLRRLAEGISEKTEAGSEEDRVRNEYEESQWTGERDTQSSTVSTTEAEPYYRSLRDFSPQLPPTQEEVSYSRGFTGEDEDMAFPGHLYDEVERTYPPSGAWGPLYDEVQMGPWDLHWPEDTYQDPRGIYDQVAGDLDTLEPDSLPFELRGHLV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Zebrafish
67
Xenopus
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O60500 As Substrate

Site PTM Type Enzyme
T414 Phosphorylation
T416 Phosphorylation
S421 Phosphorylation
S432 Phosphorylation
Y439 Phosphorylation
Y638 Phosphorylation
S700 Phosphorylation
S701 Phosphorylation
T710 Phosphorylation
T1120 Phosphorylation P17252 (PRKCA)
T1125 Phosphorylation P17252 (PRKCA)
Y1176 Phosphorylation
Y1193 Phosphorylation P06241 (FYN)
Y1217 Phosphorylation

Research Backgrounds

Function:

Seems to play a role in the development or function of the kidney glomerular filtration barrier. Regulates glomerular vascular permeability. May anchor the podocyte slit diaphragm to the actin cytoskeleton. Plays a role in skeletal muscle formation through regulation of myoblast fusion (By similarity).

PTMs:

Phosphorylated at Tyr-1193 by FYN, leading to the recruitment and activation of phospholipase C-gamma-1/PLCG1.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.
Note: Predominantly located at podocyte slit diaphragm between podocyte foot processes. Also associated with podocyte apical plasma membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Specifically expressed in podocytes of kidney glomeruli.

Subunit Structure:

Interacts with CD2AP (via C-terminal domain). Interacts with MAGI1 (via PDZ 2 and 3 domains) forming a tripartite complex with IGSF5/JAM4. Interacts with DDN; the interaction is direct. Self-associates (via the Ig-like domains). Also interacts (via the Ig-like domains) with KIRREL1/NEPH1 and KIRREL2; the interaction with KIRREL1 is dependent on KIRREL1 glycosylation. Interacts with KIRREL3. Forms a complex with ACTN4, CASK, IQGAP1, MAGI2, SPTAN1 and SPTBN1 (By similarity). Interacts with NPHS2.

Family&Domains:

Belongs to the immunoglobulin superfamily.

References

1). Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation. Journal of Translational Medicine, 2023 (PubMed: 37308949) [IF=7.4]

Application: WB    Species: Human    Sample:

Fig. 6 Effect of RES on HG-induced podocyte injury model. The relative A mRNA and B protein levels of nephrin and WT1 are downregulated in the HG group compared with those in the NC group. And treatment with RES increase the expression levels of nephrin and WT1. NC: normal control, HG: high glucose, RES: resveratrol

2). Targeted inhibition of CX3CL1 limits podocytes ferroptosis to ameliorate cisplatin-induced acute kidney injury. Molecular medicine (Cambridge, Mass.), 2023 (PubMed: 37875838) [IF=5.7]

Application: IF/ICC    Species: Mouse    Sample: kidney tissues

Fig. 1 CX3CL1 deficiency alleviated kidney function damage in cisplatin-induced model mice. WT mice and CX3CL1-KO mice received cisplatin injections at 48 h. A Examination of the kidney’s histology using representative images of H&E and PAS staining. B The serum levels of BUN and Scr were evaluated in all mice groups. C Western blotting was conducted to determine the relative expression patterns of podocin, CX3CL1, nephrin, and WT1. D Representative images of podocyte ultrastructure in kidney tissues following cisplatin injection, as shown in TEM. Scale bar = 500 nm. E Representative micrographs of CX3CL1 and nephrin staining in kidney tissues. Scale bar = 10 μm. (WT, wild type; KO, knockdown; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; BUN, blood urea nitrogen; Scr, serum creatinine; WT1, Wilms tumor protein; TEM, transmission electron microscopy; p value was calculated by one-way analysis of variance and Tukey’s test.

Application: WB    Species: Mouse    Sample: kidney tissues

Fig. 1 CX3CL1 deficiency alleviated kidney function damage in cisplatin-induced model mice. WT mice and CX3CL1-KO mice received cisplatin injections at 48 h. A Examination of the kidney’s histology using representative images of H&E and PAS staining. B The serum levels of BUN and Scr were evaluated in all mice groups. C Western blotting was conducted to determine the relative expression patterns of podocin, CX3CL1, nephrin, and WT1. D Representative images of podocyte ultrastructure in kidney tissues following cisplatin injection, as shown in TEM. Scale bar = 500 nm. E Representative micrographs of CX3CL1 and nephrin staining in kidney tissues. Scale bar = 10 μm. (WT, wild type; KO, knockdown; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; BUN, blood urea nitrogen; Scr, serum creatinine; WT1, Wilms tumor protein; TEM, transmission electron microscopy; p value was calculated by one-way analysis of variance and Tukey’s test.

3). Dl-3-n-Butylphthalide Ameliorates Diabetic Nephropathy by Ameliorating Excessive Fibrosis and Podocyte Apoptosis. Frontiers in Pharmacology, 2021 (PubMed: 34497508) [IF=5.6]

Application: IF/ICC    Species: Mice    Sample: kidney tissues

FIGURE 5 DL-NBP treatment reduces diabetes-induced podocyte apoptosis in kidney. (A,B) Western blotting and quantification of Cleaved Caspase-3 expression in each group (n = 3). (C,D) Immunofluorescence staining of Cleaved Caspase-3 (red) in kidney of db/m (control) mice, db/db mice, DL-NBP mice (db/db mice were treated with 20, 60, or 120 mg⋅kg−1 d−1 of DL-NBP) (original magnification × 400) (n = 5). Scale bar = 20 μm. (E,F) Co-staining of nephrin (red) and TUNEL (green) (original magnification × 400) was used to detect the extent of cell apoptosis in each group (n = 5). Scale bar = 20 μm. TUNEL, TdT-mediated dUTP Nick-End Labeling. All data are presented as the mean ± SEM. *p < 0.05, ***p < 0.001 vs. db/m control; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. db/db mice.

4). The Yi-Qi-Bu-Shen recipe attenuates high glucose-induced podocyte injury via the inhibition of IKK-IκBα-NFκB and ERK/P38 MAPK signaling . , 2019

Application: WB    Species: Human    Sample: podocytes

Figure 2. Effect of YB on HG-induced expression of nephrin, podocin and CD2AP in podocytes. A-C. Podocytes were treated with HG and YB for 24 hours and then mRNA levels of nephrin, podocin and CD2AP were determined by qRT-PCR. (*P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.